2
Clinical Trials associated with GH509Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)/Non-alcoholic Fatty Liver Disease (NAFLD)
This is a Phase Ib/II, randomized, double-blind, placebo-controlled, international multi-center clinical study to investigate the efficacy and safety of GH509 in subjects with NASH/NAFLD
GH509对比安慰剂治疗非酒精性脂肪性肝炎(NASH)/非酒精性脂肪性肝病(NAFLD)患者的有效性和安全性的Ib期临床研究
[Translation] Phase Ib clinical study of the efficacy and safety of GH509 versus placebo in patients with non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD)
[Translation] Phase Ib trial:
Select the Phase II recommended dose of GH509.
100 Clinical Results associated with GH509
100 Translational Medicine associated with GH509
100 Patents (Medical) associated with GH509
100 Deals associated with GH509